Minnesota has led the nation in development of evidence-based guidelines and in public reporting of performance on quality measures. A recent qualitative study explored what 21 Minnesota clinics and their affiliated medical groups are doing to provide patients with optimal diabetes and vascular care. This article reports the practices medical directors and administrators identified as contributing to the successful management of patients with these conditions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis.
Circ Heart Fail
January 2025
Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston (Y.L., J.L.J., G.D.L.).
Background: Objective indices of functional capacity in patients with diabetic cardiomyopathy and stage B heart failure (HF) have not been comprehensively defined. We sought to characterize the cardiopulmonary exercise characteristics of individuals with diabetic cardiomyopathy at high risk for overt HF.
Methods: The relationships from cardiopulmonary exercise testing with clinical and laboratory characteristics of participants with diabetic cardiomyopathy were evaluated using baseline data from the ARISE-HF trial (Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure).
High Glucose Treatment Induces Nuclei Aggregation of Microvascular Endothelial Cells via the - Pathway.
Arterioscler Thromb Vasc Biol
January 2025
Research Center of Clinical Medicine, Affiliated Hospital, Nantong University, China. (X.W., D.L.).
Background: Hyperglycemia is a major contributor to endothelial dysfunction and blood vessel damage, leading to severe diabetic microvascular complications. Despite the growing body of research on the underlying mechanisms of endothelial cell (EC) dysfunction, the available drugs based on current knowledge fall short of effectively alleviating these complications. Therefore, our endeavor to explore novel insights into the cellular and molecular mechanisms of endothelial dysfunction is crucial for the field.
View Article and Find Full Text PDFThree-Staged Surgical Hybrid Treatment for an Extended Thoracoabdominal Aneurysm in a High-Risk Patient: A Case Report.
Cureus
December 2024
Department of Cardiovascular Surgery, Shizuoka General Hospital, Shizuoka, JPN.
Thoracoabdominal aortic aneurysm (TAAA) repair remains one of the most challenging procedures and is associated with high mortality and complication rates. Careful consideration of the surgical strategy is essential, particularly in cases involving extensive replacement and high-risk patients. A 61-year-old man with a 55-mm TAAA was referred for surgical treatment.
View Article and Find Full Text PDFTherapeutic Dilemma of a Juxtapapillary Retinal Capillary Hemangioma.
Cureus
December 2024
Department of Ophthalmology and Visual Science, Ophthalmology Clinic, Hospital Universiti Sains Malaysia, Universiti Sains Malaysia, Kubang Kerian, MYS.
A juxtapapillary retinal capillary hemangioma (JRCH) is a rare vascular hamartoma located on the optic nerve head or adjacent region. While often associated with von Hippel-Lindau (VHL) disease, JRCHs can also occur as an isolated condition, presenting unique therapeutic challenges and risks of visual impairment. We report a case of a 50-year-old Malay gentleman with diabetes mellitus who presented with a non-progressive superior visual field defect in his left eye for three months.
View Article and Find Full Text PDFA systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy.
Health Technol Assess
January 2025
Centre for Reviews and Dissemination, University of York, York, UK.
Background: Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and are routinely used to treat various other eye conditions. However, anti-vascular endothelial growth factor drugs are expensive relative to current care options, and it is unclear whether this additional cost is justified when the immediate risk of vision loss is lower compared to patients with more aggressive ophthalmological conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!